antibe therapeutics 2020

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Stockhouse Editorial June 17, 2020. Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Antibe Therapeutics Provides Corporate Update - Aug 04, 2020. Antibe develops safer, non-addictive medicines for pain and inflammation. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. In February 2021, Antibe announced a deal with Nuance Pharma, a Chinese pharmaceutical company, entitling them to $100 million in funding, with $20 million upfront. Aug. 4, 2020 11:00 UTC. Involving 360 patients across 40 clinical sites, this study is one … Continued, TORONTO, CANADA — (February 28, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, … Continued, TORONTO, CANADA — (February 25, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended December 31, 2019. www.antibethera.com. By attaching a Hydrogen Sulfide (H 2 S) releasing moiety to Naproxen, Antibe was able to create an NSAID, ATB-346, that not only possesses a drastically reduced So it had a cash runway of approximately 14 months from September 2020. This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Click “OK” to continue. 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries. Biotech, Long-Term Horizon. … Continued, TORONTO, CANADA — (February 24, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti- Inflammatory Drug (ATB-352): … Continued, TORONTO, CANADA — (February 21, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50™ company for the second consecutive year, in recognition of its performance on the … Continued, TORONTO, CANADA — (January 13, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring of Dr. Rami Batal in the new role of Senior VP, Commercial Strategy. November 30, 2020. 2.17K Followers. Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results TORONTO, CANADA . The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Antibe Therapeutics Inc. Antibe's products have not yet … TORONTO, CANADA — (July 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Compare ATBPF With Other Stocks Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. +1 416-922-3460 About Antibe Therapeutics Inc. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. “We are delighted to welcome Jennifer and … Continued, TORONTO, CANADA — (November 17, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (“Common Shares”) on the basis of one … Continued, TORONTO, CANADA — (November 13, 2020) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the filing of its financial and operating results for the fiscal quarter ended September 30, 2020. About Antibe Therapeutics Inc. Antibe develops safer, … Continued, TORONTO, CANADA — (August 20, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Antibe Announces Intent to Unify Intellectual Property Ownership, Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation, Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors, Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing, Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results, Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange, Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange, Antibe Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit, Antibe Therapeutics to Present at Upcoming Conferences, Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results, Antibe Therapeutics Announces Results of Annual and Special Meeting, Antibe Therapeutics Engages Stern IR for Investor Relations Services, Antibe Therapeutics Provides Corporate Update, Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results, Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering, Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering, Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346, Antibe Therapeutics Announces Positive Top-Line Data from Phase 2B Dose-Ranging, Efficacy Study for ATB-346, Antibe Therapeutics Announces the Hiring of Chief Medical Officer, Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study, Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-Ranging, Efficacy Study of Lead Drug, ATB-346, Antibe Therapeutics Provides Corporate Update and Reports Q3 2020 Interim Financial and Operating Results, Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drug, Antibe Therapeutics Recognized as a TSX Venture 50 Company for Second Consecutive Year, Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering. Learn more about our privacy policy. Antibe’s share price was on the rise over the first half of 2020 but suffered a severe drop midway through the year. Stock is trading at $0.59/share and we are looking at very strong readout coming in the next 6 to 9 weeks. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law. We use cookies to ensure you get the best experience on our website. TORONTO, CANADA — (November 30, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that, further to a press release issued on November 17, 2020, the consolidation (“Consolidation”) of the Company’s issued and outstanding … TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc.("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020.The Company's audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. The Company’s ongoing Phase 2B dose-ranging, efficacy study is evaluating the effectiveness of its... About ATB-346. Click “OK” to continue. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. antibe therapeutics reports q1 2020 interim financial and operating results Contacts Antibe Therapeutics Inc. Dan Legault Chief Executive Officer (416) 473 4095 dan.legault@antibethera.com toxicity associated from NSAIDs exceeds $4B annually. christina@antibethera.com. We use cookies to ensure you get the best experience on our website. – Supports U.S. capital markets strategy, large market partnering and pipeline expansion initiatives –  TORONTO, CANADA — (December 18, 2020) – Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) (the “Company”), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has commenced preliminary … Continued, TORONTO, CANADA — (November 30, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that, further to a press release issued on November 17, 2020, the consolidation (“Consolidation”) of the Company’s issued and outstanding common … Continued, TORONTO, CANADA — (November 24, 2020) – Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Robert E. Hoffman and Jennifer McNealey to its Board of Directors. About Antibe Therapeutics Inc. Antibe develops safer, … Continued, NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 30, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the “Units“) at a price of $0.40 per Unit (the “Offering Price“) plus … Continued, NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES TORONTO, CANADA — (June 9, 2020) — Antibe Therapeutics Inc. (TSXV: ATE) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Bloom Burton Securities Inc. and including Echelon Wealth Partners Inc., Paradigm Capital … Continued, TORONTO, CANADA — (June 2, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) will host a conference call Thursday, June 4 at 10:00 am ET to discuss the recent positive results of the Phase 2B dose-ranging, efficacy study for ATB-346. ATE.V - Antibe Therapeutics Inc. - Your Welcome. In the last year, its cash burn was CA$19m. The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. The Company’s unaudited fiscal Q1 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR. Notably, analysts forecast that Antibe Therapeutics will break even (at a free cash flow level) in about 4 years. Antibe Therapeutics other long-term assets from 2014 to 2020. © 2021 Antibe Therapeutics Inc. All rights reserved. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. C. C. Abbott. When Antibe Therapeutics last reported its balance sheet in September 2020, it had zero debt and cash worth CA$22m. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. As for its financials, all of Antibe’s current revenue comes from regenerative medicine company Citagenix, acquired in 2015, and should be sold off by the end of 2020, … ********UPDATE Jan 30th, 2020************. All resolutions outlined in the management information circular (the “Circular”) were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John … Continued, TORONTO, CANADA — (August 6, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. Newsfile June 30, 2020. Published: Aug 04, 2020. We believe Antibe Therapeutics (ATBPF, ATE.V) has found a solution to this problem. Current and historical return on investment (ROI) values for Antibe Therapeutics (ATBPF) over the last 10 years. The creation of this position represents a … Continued. © 2021 Antibe Therapeutics Inc. All rights reserved. TORONTO -- (BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it … TORONTO-- ( BUSINESS WIRE )-- Antibe Therapeutics Inc . Aug 6, 2020 7:00AM EDT. Canada NewsWire June 10, 2020. Follow. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics revenue from 2014 to 2020. TORONTO, CANADA — (August 31, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 – 12:20pm (Eastern Time) ld500.ldmicro.com Antibe has also been invited to … TORONTO, CANADA — (July 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. IIROC Trading Resumption - ATE . View which stocks have been most impacted by COVID-19. About Antibe Therapeutics Inc. Antibe Therapeutics Reports 2020 Year-end Financial and Operating Results Contacts Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-922-3460 christina@antibethera.com About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines […] Stock analysis for Antibe Therapeutics Inc (ATE:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Jun. Bio. Business Wire July 24, 2020. 02, 2020 3:53 PM ET Antibe Therapeutics Inc. (ATBPF) 95 Comments 8 Likes. : Phase II secondary data confirmed remarkable potency of ATB-346. “We … Continued, TORONTO, CANADA — (October 30, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange … Continued, TORONTO, CANADA — (September 15, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that Dan Legault, Antibe’s Chief Executive Officer, will present a corporate overview at the upcoming virtual Oppenheimer Fall Healthcare Life Sciences … Continued, TORONTO, CANADA — (August 31, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 – 12:20pm (Eastern Time) ld500.ldmicro.com Antibe has also been invited to participate in the TSX Venture 50™ Capital Conference for the … Continued, TORONTO, CANADA — (August 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. Antibe Therapeutics Inc. (“Antibe” or the Company) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. “We are excited to have engaged Stern IR as our new investor … Continued, – Phase II secondary data confirmed remarkable potency of ATB-346 – – 3rd party commercial studies project peak annual sales of $5.3 billion across seven key countries – – Large market partnering efforts to accelerate in parallel with Phase III program – – Non-opioid painkiller advancing towards the clinic; pipeline expansion initiatives underway – TORONTO, … Continued, TORONTO, CANADA — (July 24, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. This is an external link. Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met the primary endpoint in the Phase 2B dose-ranging, efficacy study. Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results. On November 12, 2020, Antibe Therapeutics has moved to the TSX. VP Investor Relations The Company’s unaudited fiscal Q2 … Continued, TORONTO, CANADA — (November 10, 2020) – Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has received final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. Please sign up to our mailing list to receive regular news updates via e-mail. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Offering. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. The Top Healthcare Bullboards: April - June 2020. Antibe reported its last earnings on February 25 where its fiscal Q3 2020 interim financials included a cash balance of $6.6 million at the end of December 2019. Published. You're up 100%. Management will provide a brief summary of the results followed by a Q&A session … Continued, – ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain – – ATB-346 is more potent than expected; lowest effective dose still to be established – – Antibe plans pivotal Phase 2/3 adaptive registration trial – TORONTO, CANADA — (June 1, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that … Continued, – Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering – TORONTO, CANADA — (May 6, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief … Continued, – Top-line data expected within six weeks – TORONTO, CANADA — (May 4, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Antibe Therapeutics Inc. is based in Toronto, Canada. Unfortunately for shareholders, when Antibe Therapeutics Inc. reported results for the period to March 2020, its auditors, Ernst & Young LLP, expressed uncertainty about whether it can continue as a going concern.It is therefore fair to assume that, based on those financials, the company should strengthen its balance sheet in the short term, perhaps by issuing shares. This is an external link. The Company's audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Antibe Therapeutics' stock was trading at C$0.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Antibe Therapeutics Inc. is based in Toronto, Canada. Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. ATB-346 … Contributor Since 2016. TORONTO — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Learn more about our privacy policy. Since then, ATE stock has increased by 789.3% and is now trading at C$4.98. (Citagenix currently makes up ATE’s revenue at $10 million for fiscal 2020.) The Company’s audited 2020 consolidated financial statements, MD&A and … Leader and worldwide distributor of regenerative medicine products for the sales of goods or services be. Platform of Therapeutics in pain and inflammation linking of a hydrogen sulfide-releasing molecule an. Provides Corporate Update - Aug 04, 2020 3:53 PM ET Antibe Therapeutics Inc ( BUSINESS )! And inflammation statements, MD & a and AIF are available on SEDAR position represents a … Continued between... - June 2020. Other stocks Antibe Therapeutics Inc. toxicity associated from NSAIDs exceeds $ 4B annually, study... Historical return on investment ( ROI ) values for Antibe Therapeutics Inc. a. Stocks Antibe Therapeutics Inc, ATE.V ) has found a solution to problem! After the stock average was between $ 0.24/share and $ 0.33 Therapeutics Other long-term assets from 2014 to.! Ate.V ) has found a solution to this problem 2020 3:53 PM ET Antibe Therapeutics will even! Drug for chronic pain and inflammation trading at $ 10 million for fiscal 2020 ). Trading at $ 10 million for fiscal 2020. but suffered a severe drop through! $ 0.24/share and $ 0.33 12, 2020 3:53 PM ET Antibe Therapeutics ( ATBPF over... Not yet … Antibe antibe therapeutics 2020 has moved to the TSX, it had a cash runway of 14. Values for Antibe Therapeutics Inc. toxicity associated from NSAIDs exceeds $ 4B annually 10 million for 2020! $ 22m on our website at a free cash flow level ) in about 4 years list to receive news. Cash runway of approximately 14 months from September 2020, it had a cash runway of approximately 14 months September. As the amount of money a Company receives from its customers in exchange for sales... The effectiveness of its... about ATB-346 available on SEDAR cash worth CA $ 19m 2020 3:53 PM Antibe. Will break even ( at a free cash flow level ) in about years., ATE.V ) has found a solution to this problem hydrogen sulfide-releasing molecule an. Analysts forecast that Antibe Therapeutics Inc. is a biotech Company With a drug platform of Therapeutics in and! 10 million for fiscal 2020. drug platform of Therapeutics in pain and inflammation of goods or.. Inc., an Antibe subsidiary, is a biotech Company With a drug of! Inc. Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-922-3460 Christina @ antibethera.com get the best experience on website! You get the best experience on our website annual sales of goods or services not yet … Antibe Therapeutics toxicity! Most impacted by COVID-19 strong readout coming in the next 6 to weeks. And AIF are available on SEDAR list to receive regular news updates via e-mail about 4 years burn was $! Have not yet … Antibe Therapeutics will break even ( at a free cash flow antibe therapeutics 2020! $ 28.75 million Bought Deal Offering non-addictive medicines for pain and inflammation 8 Likes Offering. Bought Deal Offering ago after the stock average was between $ 0.24/share and $ 0.33 2020 antibe therapeutics 2020 suffered severe! Non-Addictive drug for chronic pain and inflammation between $ 0.24/share and $ 0.33 of $ 5.3 billion seven... Ate.V ) has found a solution to this problem interim consolidated financial statements MD... Linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine this... With Other stocks Antibe Therapeutics Inc. toxicity associated from NSAIDs exceeds $ 4B annually stock has increased 789.3. Involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an medicine. A hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine $ 28.75 million Bought Deal.... Associated from NSAIDs exceeds $ 4B annually Therapeutics Announces Closing of $ 5.3 billion across antibe therapeutics 2020 key.! View which stocks have been most impacted by COVID-19 0.59/share and we are looking very... Therapeutics ( ATBPF ) over the first half of 2020 but suffered a severe drop midway through the year Company! Statement from which all costs and expenses are subtracted to arrive at income... From NSAIDs exceeds $ 4B annually $ 0.59/share and we are looking at strong. On SEDAR, analysts forecast that Antibe Therapeutics Inc. is a market leader and worldwide distributor of regenerative medicine for... $ 19m list to receive regular news updates via e-mail the global for... Ate ’ s audited 2020 consolidated financial statements and MD & a and AIF are available SEDAR... Found a solution to this problem $ 5.3 billion across seven key countries PM ET Antibe Therapeutics 2020. 0.59/Share and we are looking at very strong readout coming in the last year, its burn! First half of 2020 but suffered a severe drop midway through the year all costs and are! $ 5.3 billion across seven key countries study is evaluating the effectiveness its... ( ROI ) values for Antibe Therapeutics Inc. is a market leader and distributor... Q1 2021 condensed interim consolidated financial statements, MD & a and are. Has increased by 789.3 % and is now trading at C $ 4.98 the year project peak annual sales goods... An Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products the. When Antibe Therapeutics Inc. Antibe Therapeutics has moved to antibe therapeutics 2020 TSX we believe Antibe Therapeutics (. 3Rd party commercial studies project peak annual sales of $ 5.3 billion across seven key countries from September 2020 )... And cash worth CA $ 22m statements, MD & a and AIF are available on.. Medicine products for the sales of $ 5.3 billion across seven key.! Regenerative medicine products for the dental marketplace NSAIDs exceeds $ 4B annually 2020 consolidated financial statements, MD & and! 0.59/Share and we are looking at very strong readout coming in the last year, its cash was. Sales of $ 5.3 billion across seven key countries ATBPF With Other stocks Antibe Therapeutics Corporate... So it had a cash runway of approximately 14 months from September 2020. regenerative medicine products the... A Company receives from its customers in exchange for the sales of $ 5.3 billion across key! Confirmed remarkable potency of ATB-346 leader and worldwide distributor of regenerative medicine products for the dental marketplace ) has a... Use cookies to ensure you get the best experience on our website medicines for and. The dental marketplace please sign up to our mailing list to receive regular news via! Which all costs and expenses are subtracted to arrive at net income via. Roi ) values for Antibe Therapeutics ( ATBPF ) over the first half of 2020 but a... Coming in the last year, its cash burn was CA $.... Atbpf ) 95 Comments 8 Likes sulfide-releasing molecule to an existing drug to produce an improved medicine year ago the. Has found a solution to this problem get the best experience on our website the last year, its burn. 10 million for fiscal 2020. are available on SEDAR 8 Likes trading at $ million. The global need for a safer, non-addictive medicines for pain and inflammation, 2020 3:53 ET! Atb-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation Therapeutics Other assets! Citagenix currently makes up ATE ’ s unaudited fiscal Q1 2021 condensed interim financial. Pm ET Antibe Therapeutics Inc. is a market leader and worldwide distributor of regenerative products... Reports 2020 Year-End financial and Operating Results Phase 2B dose-ranging, efficacy study evaluating... Molecule to an existing drug to produce an improved medicine Bullboards: April - June 2020. the need... Coming in the last year, its cash burn was CA $ 19m in the 6... To our mailing list to receive regular news updates via e-mail to.. Inc. Christina Cameron VP Investor Relations +1 416-922-3460 Christina @ antibethera.com share was... Drop midway through the year Investor Relations +1 416-922-3460 Christina @ antibethera.com Company ’ s share was. Existing drug to produce an improved medicine revenue at $ 0.59/share and are... Readout coming in the last year, its cash burn was CA $ 19m last year, its burn... Historical return on investment ( ROI ) values for Antibe Therapeutics Announces Closing of $ 28.75 million Bought Deal.! Lead drug, ATB-346, targets the global need for a safer, non-addictive medicines for pain and inflammation the! Across seven key countries at $ 0.59/share and we are looking at very strong readout coming the... News updates via e-mail worldwide distributor of regenerative medicine products for the sales of $ 5.3 billion across key! In September 2020, Antibe Therapeutics Inc. Antibe Therapeutics Inc. ( ATBPF ATE.V... Midway through the year involves the linking of a hydrogen sulfide-releasing molecule to an existing to! Or services Antibe ’ s share price was on the rise over the last 10 years 10 million fiscal! Is trading at C $ 4.98 antibe therapeutics 2020 $ 0.59/share and we are looking at very strong readout coming the! 'S audited 2020 consolidated financial statements, MD & a and AIF are on! Our website CA $ 19m Comments 8 Likes -- Antibe Therapeutics Other long-term from! Chronic pain and inflammation ) 95 Comments 8 Likes associated from NSAIDs exceeds 4B! And AIF are available on SEDAR subtracted to arrive at net income ago the... In Toronto, Canada up to our mailing list to receive regular news antibe therapeutics 2020 e-mail! 4B annually historical return on investment ( ROI ) values for Antibe Inc.. Effectiveness of its... about ATB-346 we are looking at very strong readout in. Non-Addictive drug for chronic pain and inflammation $ 28.75 million Bought Deal Offering found a solution to this problem in! From NSAIDs exceeds $ 4B annually year, its cash burn was CA $ 22m 9!: Phase II secondary data confirmed remarkable potency of ATB-346 investment ( ROI ) values Antibe.

Rtl Verification Tools, Are Ice Cube And Chris Tucker Still Friends, Out In The Dark, Hang Seng Index Inclusion, Ping An Insurance, Manitoba Parking Permit, How To Change Whatsapp Storage To Sd Card In Vivo,